Reaction of 5-aryloxazolidines with arylmagnesium bromides as a new route to N-benzyl-β-hydroxyphenethylamines as starting materials for the preparation of 4-aryl-1,2,3,4-tetrahydroisoquinolines by Moshkin, V. S. & Sosnovskikh, V. Y.
Tetrahedron Letters 54 (2013) 2699–2702Contents lists available at SciVerse ScienceDi rect 
Tetrahedro n Letters 
journal homepage: www.elsevier .com/ locate/ tet le tReaction of 5-aryloxazolidines with arylmagnesium bromides 
as a new route to N-benzyl-b-hydroxyphenethylamines as starting materials 
for the preparation of 4-aryl-1,2,3,4-tetrahydroisoquinolines 
Vladimir S. Moshkin ⇑, Vyacheslav Ya. Sosnovskikh 
Department of Chemistry, Ural Federal University, prosp. Lenina 51, 620000 Ekaterinburg, Russia a r t i c l e i n f o
Article history: 
Received 26 January 2013 
Revised 27 February 2013 
Accepted 13 March 2013 
Available online 23 March 2013 
Keywords:
4-Aryl-1,2,3,4-tetrahydroisoquinolines
5-Aryloxazolidines
Non-stabilized azomethine ylide 
[3+2] Cycloaddition 
Cyclization reaction 0040-4039/$ - see front matter  2013 Elsevier Ltd. A
http://dx.doi.org/10.1016/j.tetlet.2013.03.076
⇑ Corresponding author. Fax: +7 343 261 59 78. 
E-mail address: mvslc@mail.ru (V.S. Moshkin).a b s t r a c t
Benzaldehydes react smoothly with the non-stabilized azome thine ylide derived from sarcosine and 
formaldehyde to form 5-aryloxazolidines as intermediates, which undergo ring-op ening to give 
N-benzyl-b-hydroxyphenethylamines in good yields by the action of arylmagnesium bromides. Their 
subsequent acid-catalyzed cyclization into 4-aryl-1,2,3,4-tetrahydroisoquinolines was performed in 
moderate to good yields. 
 2013 Elsevier Ltd. All rights reserved. N
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NThe chemistry of 4-aryl-1,2,3,4-tetr ahydroisoquinol ines has at- 
tracted considerable attention from the synthetic community due 
to their distribution in Nature and various biological activities. 1
Amaryllidac eae alkaloids such as cherylline (1) and latiﬁne (2) have 
been isolated from Crinum latifolium and other Crinum species.2
Nomifensine (3), a serotonin–norepinephrine–dopamine reuptake 
inhibitor, was marketed as an antidepress ant in the 1970–
1980s.3 Furthermor e, a large number of 4-aryltetr ahydroisoquino- 
lines4 and their hetero analogs 5 have been proposed as triple 
monoamine reuptake inhibitors , anti-ulce r and antihistamine 
drugs, for example, 4-(4-bromophenyl)-2-methyl-1,2,3,4- tetrahy- 
droisoquinol ine (4)6 (Fig. 1).
Due to the important applications of this class of compounds ,
their synthesis has been studied extensive ly. There are several 
routes for the preparation of 4-aryltetrahyd roisoquinolines , with 
most of them being complete d via the intramolecu lar cyclization 
of N-benzyl-b-hydroxyphene thylamines. 4–7 The latter are obtained 
by the reaction of phenacyl bromides and benzylamines followed 
by a reduction step, 4a–d,6,7a or from styrene oxides and benzylam- 
ines.7b,c In addition, there are a number of alternative methods 
based on Pictet-Spengl er cyclization of 2,2-diarylet hylamines, 8
the addition of lithium benzylamides to acetophenone enols, 9 di-
rect deprotonation of C-4 in 1,2,3,4-tetra hydroisoqui nolines using ll rights reserved. sec-butyllithiu m, and subsequent arylation using aryl halides via 
aryne intermedi ates. 10
In connectio n with our interest in the development of azome- 
thine yl id e ch emi st ry ,11 we ha ve de ve lo pe d a con ven ie nt , on e- po t
me th od fo r th e pr ep ar ati on of 2- me thy l- 1, 2,3 ,4 -t et ra hy dr oi so qu in o- 
li n- 4-o ls 5 fr om ar om at ic ald eh yd es be ari ng el ec tr on -d ona tin g
su bs ti tu en ts and an azo me th in e yl id e de ri ve d fr om sa rc osi ne an dMe
4
Me
3NH2
Figure 1. Some natural alkaloids and drugs containing a 4-aryltetrahydroisoquin- 
oline framework. 
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Scheme 1. One-pot syntheses of substituted tetrahydroisoquinolines. 
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Scheme 2. Synthesis of N-benzyl-b-hydroxyphenethylamines 7 and 4-aryltetrahy- 
droisoquinolines 8.
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re arr ang em en t. 12 In th is in tra mo le cu la r ele ct ro ph il ic su bs tit ut io n
re act io n, in te rm ed ia te im in iu m cat io n A re ac ts wit h the nu cl eo ph il ic 
ar ene wi th fo rm at io n of the te tr ah yd ro is oqu in ol in e ri ng sy st em 5.
Ta ki ng in to ac co unt th is re su lt , we en vi sa ge d th at th e ri ng -o pe ni ng
of ox azo li di ne 6 by an ext er na l nu cl eo ph il ic ar ene wou ld pr od uce 
th e co rr es po nd in g N-b en zy l- b-h yd ro xy ph en eth yl ami ne, th e ke y
in ter me di at e fo r ou r 4- ary l- 1,2 ,3, 4-t et ra hy dr oi so qu in ol in e sy nt he -
si s. To th e bes t of ou r kn ow le dg e, no su ch re ac ti on s ha ve be en 
re po rt ed to da te (Sc hem e 1).Table 1
Yields and melting points of N-benzyl-b-hydroxyphenethylamine s 7 and 4-aryltetrahydro
Amino alcohol Yield (%)
OH
N
Me
7a
71
OH
N
Me
Br 7b 82
OH
N
Me
MeO
7c
76
OH
N
Me
O
O
7d
58We found that reﬂuxing an aromatic aldehyde (1.0 mmol), sar- 
cosine (1.5 mmol), and paraformald ehyde (3.0 mmol), in benzene 
or toluene for 6–8 h with azeotropic removal of water, allowed isoquinolines 8
Tetrahydroisoquinoline Yield a (%) Mp b (C)
N
Me
8a
56 167–172c
N
Me
Br
8b
60 247–252d
N
Me
OMe
8c
32 207–215e
N
Me
O
O
8d
37 237–240f
Table 1 (continued)
Amino alcohol Yield (%) Tetrahydroisoquinoline Yield a (%) Mp b (C)
OH
N
Me
O
O
MeO 7e 54
N
Me
O
O
OMe
8e
39 230–235
OH
N
Me
Br
S
7f 79
N
MeS
Br
8f
65 217–224
OH
N
Me
MeO
7g
65 — — —
OH
N
Me
MeO
MeO
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7h
79 — — —
OH
N
Me
O
O
7i
88 — — —
a Overall yield of the hydrochlorides based on the starting aromatic aldehyde. 
b Mp of the hydrochlorides, uncorrected. 
c Mp 169–174 C (Ref. 7a).
d Mp 245–250 C (Ref. 6b).
e This compound was recrystallized from i-PrOH–Et2O; reported in Ref. 10 as a free base. 
f Mp 237–239 C (Ref. 7c), 212–214 C (Ref. 7a).
V. S. Moshkin, V. Ya. Sosnovskikh / Tetrahedron Letters 54 (2013) 2699–2702 2701us to obtain 5-aryloxa zolidines 6 in high yields. 12,13 The crude oily 
products were sufﬁciently pure according to the 1H NMR spectra, 
and were used in the next stage without puriﬁcation. Arylmagne- 
sium bromides were prepared from aryl bromides (1.5 mmol)
and magnesium (1.5 mmol) in THF according to the standard tech- 
nique. To our delight, simple addition of oxazolidi ne 6 to a solution 
of the arylmagnesi um bromide resulted in full opening of cyclic 
aminal 6, and subsequent acidiﬁcation led to the desired 2-(ben-
zylmethylam ino)-1-arylethanols 7a–i (Scheme 2, Table 1).14 The
hydrochlori des of these compounds had different solubilities in 
water, so the best technique for their puriﬁcation involved direct 
precipitatio n as a mixture with the magnesium salt from the 
THF–toluene solution, followed by washing to remove non-basic 
organic side products, and ﬁnal basiﬁcation of the salt mixture 
with concentrated aqueous NH 3.
Intramolecul ar cyclization of N-benzyl-b-hydroxyphene thyl- 
amines 7a–c was performed under previously described 
conditions (CH2Cl2, RT, H2SO4;6,7a–c for 7c—AlCl34e,f) to give 
4-aryltetrahy droisoquinolin es 8a–c in moderate to good yields 
based on the starting aromatic aldehyde. Similarly, compounds 
8d,e bearing an electron-donati ng methylened ioxy substituent 
on the aromatic ring were obtained in 37% and 39% yields, respec- 
tively.15,16 Application of this reaction to 2-thieny lmagnesium bromide led to a three-step synthesis of 4-(4-bromophenyl)-
6-methy l-4,5,6,7-tetrahy drothieno[2,3- c]pyridine (8f)17 in 65% 
yield, as a potential selective 5-HT reuptake inhibitor. 5c In this 
case, the cyclization step was performed under the action of 
PPA7f,g (Scheme 2). It should be noted that the structure of 
thienopy ridine 8f needed additional conﬁrmation because of the 
known possibility of isomeriz ation via a spirocyclic rearrange -
ment.7g This compound was thus identiﬁed by comparison of its 
1H NMR spectral data with those reported in the literature (the
chemical shift of the H-3 thienyl proton at d 6.52 showing an 
upﬁeld shift due to shielding by the phenyl ring).
In a few cases (amino alcohols 7g–i), recognizable products 
could not be isolated, presumably due to the stabilizing effect of 
the p-alkoxy group on the initial benzylic carbocation intermedi -
ate, which makes cyclization difﬁcult and facilitates intermolecu lar 
side reactions leading to the formatio n of resinous products. In the 
course of this study, N-benzyl-b-hydroxyp henethylamines 7c,e,f
and 4-aryltetrahy droisoquinolin es 8e,f have been synthesized for 
the ﬁrst time, while the other compounds were previously known. 
The results are compiled in Table 1.
It is worth noting that compared with the previousl y known ap- 
proaches for the synthesis of 4-aryl-1,2,3,4- tetrahydroisoqui no- 
lines, the present method does not require the use of a reducing 
2702 V. S. Moshkin, V. Ya. Sosnovskikh / Tetrahedron Letters 54 (2013) 2699–2702agent, and does not involve working with hazardous compounds ,
an inert atmosph ere, or chromatographi c puriﬁcation of the inter- 
mediate liquid products, and thereby greatly facilitates the prepa- 
ration of the target tetrahydroisoqui nolines. 
In conclusion, we have develope d a new, three-step route to 4- 
aryl-1,2,3,4-tet rahydroisoq uinolines from aromatic aldehydes, sar- 
cosine, and formaldehyd e via a 5-aryloxazolidi ne intermediate, fol- 
lowed by the reaction with an arylmagnes ium bromide and ﬁnal
acid-catalyzed cyclization. This method allows easy access to bio- 
logically important tetrahydroisoqui noline derivatives. Further 
application of this reaction for the construction of substituted tet- 
rahydroisoq uinolines and their hetero analogs is underway in our 
laboratory and the results will be reported in due course. 
Acknowled gment 
This work was supported ﬁnancially by the RFBR (Grant 12-03- 
31036).
References and notes 
1. (a)Chemistry of Heterocyclic Compounds: Isoquinolines ; Taylor, E. C., Weissberger, 
A., Eds.; John Wiley & Sons: New York, 1981, 1990, 1995; Vol. 38, Parts 1–3; (b);
Charifson, P. S. Drugs Future 1989, 14, 1179–1185; (c) Shklyaev, Yu. V.; Kartsev, 
V. G. Some 1,2,3,4-tetrahydroisoquinoline alkaloids of the 1-benzylisoquinoline 
group. In Nature Isoquinoline Chemistry and Biological Activity ; Kartsev, V. G., 
Ed.; IBS Press: Moscow, Russia, 2011; Vol. 8, pp 386–695.
2. (a) Brossi, A.; Grethe, G.; Teitel, S.; Wildman, W. C.; Bailey, D. T. J. Org. Chem. 
1970, 35, 1100–1104; (b) Kobayashi, S.; Tokumoto, T.; Taira, Z. J. Chem. Soc., 
Chem. Commun. 1984, 1043–1044.
3. (a) Hoffmann, I.; Ehrhart, G.; Schmitt, K. Arzneim. Forsch. 1971, 21, 1045; (b)
Hunt, P.; Kannengiesser, M. H.; Raynaud, J. P. J. Pharm. Pharmacol. 1974, 26,
370–371.
4. (a) Molino, B. F.; Berkowitz, B.; Cohen, M. US Patent 20060111394, Chem. Abstr. 
2006, 144, 488538.; (b) Molino, B. F.; Liu, S.; Berkowitz, B. A.; Guzzo, P.; Beck, J. 
P.; Cohen, M. WO Patent 2006020049, Chem. Abstr. 2006, 144, 254149.; (c)
Pechulis, A. D.; Beck, J. P.; Curry, M. A.; Wolf, M. A.; Harms, A. E.; Xi, N.; Opalka, 
C.; Sweet, M. P.; Yang, Z.; Vellekoop, A. S.; Klos, A. M.; Crocker, P. J.; Hassler, C.; 
Laws, M.; Kitchen, D. B.; Smith, M. A.; Olson, R. E.; Liu, S.; Molino, B. F. Bioorg.
Med. Chem. Lett. 2012, 22, 7219–7222; (d) Deng, X.; Liang, J. T.; Liu, J.; 
McAllister, H.; Schubert, C.; Mani, N. S. Org. Process Res. Dev. 2007, 11, 1043–
1050; (e) Jacob, J. N.; Nichols, D. E.; Kohli, J. D.; Glock, D. J. Med. Chem. 1981, 24,
1013–1015; (f) Riggs, R. M.; Nichols, D. E.; Foreman, M. M.; Truex, L. L. J. Med. 
Chem. 1987, 30, 1887–1891.
5. (a) Schneider, C. S.; Weber, K. H.; Langbein, A.; Bechtel, W. D.; Boeke, K. DE 
Patent 2746443, 1979; Chem. Abstr. 1979, 91, 456978.; (b) Schneider, C. S.; 
Weber, K. H.; Langbein, A.; Bechtel, W. D.; Boeke, K. DE Patent 2833378, 1980; 
Chem. Abstr. 1980, 93, 426418.; (c) Schneider, C. S.; Weber, K. H.; Daniel, H.; 
Bechtel, W. D.; Boeke-Kuhn, K. J. Med. Chem. 1984, 27, 1150–1155; (d) Riggs, R. 
M.; Nichols, D. E.; Foreman, M. M.; Truex, L. L.; Glock, D.; Kohli, J. D. J. Med. 
Chem. 1987, 30, 1454–1458.
6. (a) Mondeshka, D. M.; Ivanova, N. S.; Ivanov, C. B.; Angelova, I. G.; Boyadjiev, S. 
E.; Tancheva, C. N.; Tersiiska, S. A.; Tosheva, M. R.; Parashikov, V. A.; Paskov, V. 
D.; Velkov, V. A. EP Patent 400319, 1990; Chem. Abstr. 1992, 116, 6435.; (b)
Mondeshka, D. M.; Angelova, I. G.; Tancheva, C. N.; Ivanov, C. B.; Daleva, L. D.; 
Ivanova, N. S. Farmaco 1994, 49, 475–480.
7. (a) Venkov, A. P.; Vodenicharov, D. M. Synthesis 1990, 253–255; (b) Hara, H.; 
Shirai, R.; Hoshino, O.; Umezawa, B. Heterocycles 1983, 20, 1945–1950; (c) Hara, 
H.; Shirai, R.; Hoshino, O.; Umezawa, B. Chem. Pharm. Bull. 1985, 33, 3107–
3112; (d) Anan, H.; Tanaka, A.; Tsuzuki, R.; Yokota, M.; Yatsu, T.; Fujikura, T. Chem. Pharm. Bull. 1996, 44, 1865–1870; (e) Coote, S. J.; Davies, S. G.; Fletcher, 
A. M.; Roberts, P. M.; Thomson, J. E. Chem. Asian J. 2010, 5, 589–604; (f)
Maffrand, J. P.; Boigegrain, R.; Courregelongue, J.; Ferrand, G.; Frehel, D. J.
Heterocycl. Chem. 1981, 18, 727–734; (g) Mackay, C.; Waigh, R. D. J. Chem. Soc., 
Chem. Commun. 1982, 793–794; (h) Philippe, N.; Denivet, F.; Vasse, J.-L.; 
Sopkova-de Olivera Santos, J.; Levacher, V.; Dupas, G. Tetrahedron 2003, 59,
8049–8056.
8. Ruchirawat, S.; Tontoolarug, S.; Sahakitpichan, P. Heterocycles 2001, 635–
640.
9. Crecente-Campo, J.; Vázquez-Tato, M. P.; Seijas, J. A. Tetrahedron 2009, 65,
2655–2659.
10. Singh, K. N.; Singh, P.; Singh, P.; Deol, Y. S. Org. Lett. 2012, 14, 2202–2205.
11. (a) Moshkin, V. S.; Sosnovskikh, V. Y.; Slepukhin, P. A.; Röschenthaler, G.-V. 
Mendeleev Commun. 2012, 22, 29–31; (b) Moshkin, V. S.; Sosnovskikh, V. Y.; 
Röschenthaler, G.-V. Tetrahedron Lett. 2012, 53, 3568–3572.
12. Moshkin, V. S.; Sosnovskikh, V. Y. Tetrahedron Lett. 2013, 54, 2455–2457.
13. (a) Nyerges, M.; Fejes, I.; Virányi, A.; Groundwater, P. W.; Töke, L. Synthesis
2001, 1479–1482; (b) Ryan, J. H.; Spiccia, N.; Wong, L. S.-M.; Holmes, A. B. Aust.
J. Chem. 2007, 60, 898–904.
14. General procedure for the preparation of 4-aryl-1,2,3,4-tetrahydroisoquinolines 8.
A mixture of the substituted benzaldehyde (1.0 mmol), ﬁnely ground sarcosine 
(0.13 g, 1.5 mmol), and paraformaldehyde (0.09 g, 3.0 mmol) was reﬂuxed in 
dry benzene (3.3 mL), with magnetic stirring and removal of formed water by 
means of a Dean–Stark trap, for 6–8 h. The resulting solution was evaporated in 
vacuo to give the oily 5-aryl-3-methyloxazolidine 6. This was dissolved in 
toluene (1 mL) and quickly added to a solution of ArMgBr prepared from ArBr 
(1.5 mmol) and Mg (0.04 g, 1.5 mmol) in THF (2 mL) at 0 C with vigorous 
stirring. The mixture was left overnight at room temperature. Concentrated 
HCl (0.25 mL, 3.0 mmol) and toluene (3 mL) were added with stirring to the 
cooled solution (5 C). The organic layer was decanted and the precipitate 
additionally washed with toluene and Et 2O. After basiﬁcation with an excess of 
aq NH 3, extraction with CH 2Cl2 (2  2 mL), drying over Na 2SO4, and 
evaporation, the corresponding N-benzyl-b-hydroxyphenethylamine 7 was
obtained. This was dissolved in CH 2Cl2 (2 mL) and treated dropwise with concd 
H2SO4 (2 mL) (96%—for 7a,b, 75%—for 7d,e) over 5 min. After stirring for 2 h, ice 
chips were added and the aq solution made basic with aq NaOH solution. The 
mixture was extracted with CH 2Cl2 (2  2 mL) and the combined organic 
extracts dried over anhydrous Na 2SO4, ﬁltered through a thin layer of silica gel 
and concentrated in vacuo. Amino alcohols 7c and 7f were cyclized using AlCl 3
in CH 2Cl2 (4.0 equiv, reﬂux, 1.5 h) and polyphosphoric acid (1.1 g of PPA—
1 mmol of 7f, 80–90 C, 1.5 h), respectively. The free bases were converted into 
hydrochloride salts with anhydrous ethereal HCl solution generated in situ 
from i-PrOH (1.3 equiv) and AcCl (1.1 equiv).
15. 4-(4-Bromophenyl)-2-methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride 
(8b„4). White powder, yield 60% (overall yield based on the starting 
aromatic aldehyde), mp 247–252 C (245–250 C in Ref. 6b).
16. 8-(4-Methoxyphenyl)-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline 
hydrochloride (8e). White powder, yield 39%, mp 230–235 C. 1H NMR 
(400 MHz, CDCl 3, free base) d 2.40 (s, 3H, MeN), 2.47 (dd, J = 11.3, 8.8 Hz, 1H, 
7-CHH), 2.96 (dd, J = 11.3, 5.5 Hz, 1H, 7-CH H), 3.50 (d, J = 14.5 Hz, 1H, 5-C HH),
3.63 (d, J = 14.5 Hz, 1H, 5-CH H), 3.79 (s, 3H, MeO), 4.11 (t, J = 7.0 Hz, 1H, H-8),
5.85 (s, 2H, H-2), 6.32 (s, 1H, H-9), 6.52 (s, 1H, H-4), 6.83 (d, J = 8.6 Hz, 2H, Ar),
7.10 (d, J = 8.6 Hz, 2H, Ar); 13C NMR (126 MHz, DMSO- d6, for the hydrochloride)
d 41.0, 42.2, 53.6, 55.1, 55.9, 101.2, 105.9, 107.8, 114.3, 122.2, 128.8, 130.0, 
132.7, 146.3, 146.9, 158.6. Anal. Calcd for C18H20ClNO30.25H2O: C, 63.90; H, 
6.11; N, 4.14. Found: C, 63.76; H, 6.20; N, 4.08. 
17. 4-(4-Bromophenyl)-6-methyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine
hydrochloride (8f). Light yellow powder, yield 65%, mp 217–224 C. 1H NMR 
(400 MHz, CDCl 3, free base) d 2.46 (s, 3H, MeN), 2.51 (dd, J = 11.6, 8.0 Hz, 1H, 5- 
CHH), 3.00 (dd, J = 11.6, 5.5 Hz, 1H, 5-CH H), 3.66 (d, J = 14.5 Hz, 1H, 7-C HH),
3.77 (d, J = 14.5 Hz, 1H, 7-CH H), 4.10 (dd, J = 8.0, 5.5 Hz, 1H, H-4), 6.52 (d,
J = 5.1 Hz, 1H, H-3), 7.04–7.08 (m, 1H, H-2), 7.07 (d, J = 8.2 Hz, 2H, Ar), 7.41 (d,
J = 8.2 Hz, 2H, Ar); 13C NMR (126 MHz, DMSO- d6, for the hydrochloride) d 39.9,
42.3, 50.9, 55.7, 120.8, 125.6, 126.2, 128.0, 130.6, 131.7, 135.3, 139.3. Anal. 
Calcd for C14H15BrClNS: C, 48.78; H, 4.39; N, 4.06. Found: C, 49.08; H, 4.36; N, 
4.08.
